Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases
July 14, 2023
PDF 104.6 KB
DownloadVersanis is progressing a first-in-class therapy to address one of the most prevalent and urgent chronic disease epidemics of our time.
Versanis is the first to tackle obesity by targeting activin type II receptors (ActRII), the activin receptors found in both fat and muscle cells. Signaling through ActRII receptors causes wasting in muscles and storage of fat in adipose tissue. Human genetic studies have implicated members of the activin pathway in obesity.
Human Health
Industry
Biotech
Status
Realised